Le Lézard
Classified in: Health, Business
Subject: ATY

AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation Of AbbVie Inc. - ABBV


NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) resulting from allegations that AbbVie and/or its executives may have issued materially misleading business information to the investing public.

Bernstein Liebhard LLP.  (PRNewsFoto/Bernstein Liebhard LLP) (PRNewsfoto/Bernstein Liebhard LLP)

If you purchased AbbVie securities, and/or would like to discuss your legal rights and options, please visit AbbVie Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or [email protected].

On September 18, 2018, Bloomberg reported that "California's insurance regulator is suing AbbVie Inc., alleging that the pharmaceutical giant gave illegal kickbacks to health-care providers in order to keep patients on its blockbuster rheumatoid arthritis drug Humira." The report further stated that, according to the California Department of Insurance, "[t]he company 'engaged in a far-reaching scheme including both classic kickbacks -- cash, meals, drinks, gifts, trips, and patient referrals -- and more sophisticated ones -- free and valuable professional goods and services to physicians to induce and reward Humira prescriptions.'"

On this news, AbbVie stock fell $4.35 per share, or over 4.5%, over two consecutive trading days to close at $91.02 per share on September 19, 2018, damaging investors.

If you purchased AbbVie securities, and/or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/abbvie-inc-abbv-lawsuit-class-action-fraud-stock-84/ or contact Daniel Sadeh toll free at (877) 779-1414 or [email protected].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information
Daniel Sadeh
Bernstein Liebhard LLP
http://www.bernlieb.com
(877) 779-1414
[email protected]

 

SOURCE Bernstein Liebhard LLP


These press releases may also interest you

at 09:20
Coronis Health, a trusted partner for laboratory and pathology revenue cycle management (RCM), will be a leading voice at the upcoming Executive War College (EWC) 2024 conference from April 30 to May 1 in New Orleans. As the premier forum for...

at 09:18
PRUVN Research LLC, [PRUVN], a leading research organization validating wellness products and services, is excited to announce the results of its recent preliminary study with Max International, investigating the impact of RiboCeinetm supplementation...

at 09:15
After graduating from Cornell University, Daphni Sawyer worked in healthcare for more than two years before she decided to pursue an advanced degree. In May, she will graduate with two master's degrees from Rutgers. ...

at 09:15
Thirty Madison, the specialty telemedicine company operating Keeps, Cove, and Nurx, today announced a partnership with Talkspace, a  leading online behavioral health company, to expand comprehensive mental health offerings for more than half a...

at 09:15
RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today it has successfully closed its first seed funding round, raising $16.5 million to propel its mission to develop and...

at 09:15
Evive Brands, a leading name in the health and home services sector, announced today that all four of its flagship brands have been named to FranServe's  FRAN-TASTIC 500 list....



News published on and distributed by: